Cancer therapeutics and research: novel developments

First paragraph (this article has no abstract) 
Current cancer treatment still faces many challenges, while drug development and consequently novel treatments lag behind. Treatment of cancer has made tremendous progress in the last few

of Cancer Research. However, not each category is equally distributed, and we aim to attract more papers in the field of genetics and genomics, knowledge which can be applied to personalize treatment with either DNA targeted drugs, protein kinase targeted drugs, combinations or a combination with modern radiotherapeutic approaches such as 3-and 4-dimensional radiation. Selection of patients is the future, such as being investigated in several large prospective studies which perform either whole genome sequencing or limited screening for a few genes. In general, sequencing of the whole genome in large groups will help to identify potential druggable targets, while screening for a few selected genes will be more useful to identify patients most likely to respond to a certain treatment.
With the dedicated help of the senior editors Piero Picci, Hallgeir Rui, Paolo Fortina, Jacques E. Nor and Jiaoti Huang we have been able to warrant a high quality in different fields. They have a large experience covering many fields of cancer research, and have been supported by critical reviewers who reviewed rigorously the submitted papers. Of these submissions 55% has been rejected after initial review and evaluation, by either the senior editor or by the Editor-In-Chief. Hence, quality was assured in this process. Accepted manuscripts cover several areas such as research on a large variety of topics (apoptosis, cell cycle modulation, surgery, radiation, cachexia, tyrosine kinases, prevention, biomarkers) [2,3,4], clinical studies (covering many cancers, mostly focusing on single-institutional studies, although large databases also were used) [5], novel methodologies (metronomic therapy, but also radiation and surgical approaches) [5,6,7,8,9], and case reports (Figure 1). The latter was somewhat surprising and had special attention of the editors, since a case report should really describe novel aspects of a certain disease. A good case report will focus on unexpected findings in certain patients or patients group, and therefore needs to be very focused not only on findings in such patients but also be able to put these data in a wider perspective. Additionally, several reviews [8,10] and hypothesis generating papers [11] were published.
Where are we heading? The Journal has made an excellent start, since it is not easy to attract high quality papers. However, to become visible, to be covered by indexing sources such as PubMed, and to attract more

Cancer Therapeutics & Research ISSN 2049-7962
outstanding manuscripts, the current strict editorial policy has to be maintained and even strengthened more. The Journal is on the right track, although there is much competition in this field, but the publisher is dedicated to provide the resources to maintain the current quality of the papers and the rapid review process. We continue to attract exciting papers on various topics. Because of the rapid processing (time between submission and final acceptance 45 days), publication (within 7 days after acceptance) will be timeless. We solicit, among various items, high quality research papers, reviews on contempary topics and reports on clinical studies.

Competing interests
The author declare that they have no competing interests.

Acknowledgement
I thank the senior editors, the editorial board members and the reviewers for their continuing efforts in reviewing papers and the senior editors for their comments to this editorial. I also want to thank the excellent support from the editorial office members during the first year and for providing me with the information to write this editorial.